Preparation, physicochemical and biopharmaceutical characterization of oxcarbazepine-loaded nanostructured lipid carriers as potential antiepileptic devices

Montoto, Sebastián Scioli; Muraca, Giuliana; Ianni, M. Di; Couyoupetrou, Manuel; Pesce, Guido; Islan, Germán Abel; Chain, Cecilia Yamil; Vela, María Elena; Ruiz, María Esperanza; Talevi, Alan; Castro, Guillermo R.

doi:10.1016/j.jddst.2021.102470

Cited by 11 publications

(6 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They observed an enhanced permeability of the encapsulated drug compared to the free OXCBZ into MDCK‐MDR1 cells. Also, they concluded that there was not interaction between de NLC with studied immunoglobulins or bovine serum albumin, but this investigation should be confirmed by in vivo studies 60 …”

Section: Biodegradable Nanoparticles For Epilepsymentioning

confidence: 94%

See 1 more Smart Citation

Biodegradable nanoparticles for the treatment of epilepsy: From current advances to future challenges

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Biodegradable Nanoparticles For Epilepsymentioning

confidence: 94%

“…Also, they concluded that there was not interaction between de NLC with studied immunoglobulins or bovine serum albumin, but this investigation should be confirmed by in vivo studies. 60 …”

Section: Biodegradable Nanoparticles For Epilepsymentioning

confidence: 99%

Biodegradable nanoparticles for the treatment of epilepsy: From current advances to future challenges

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Oxcarbazepine was released by the mixed mechanism of both diffusion and rearrangement of polymeric chains of the coating. In vitro surface plasmon resonance (SPR) studies were performed and the results concluded that no interaction was observed between plain NLC, PVA-coated NLC, and IgG, IgM, or BSA antibodies and therefore increase in the circulation time of the formulation can be suggested [48].…”

Section: Nanocarriers For Oxcarbazepine Drugmentioning

confidence: 99%

Nanotechnological advances in the treatment of epilepsy: a comprehensive review

Rai,

Sharma,

Bhasin

et al. 2024

Nanotechnology

View full text Add to dashboard Cite

Epilepsy is one of the most prevalent chronic neurological disorders characterized by frequent unprovoked epileptic seizures. Epileptic seizures can develop from a broad range of underlying abnormalities such as tumours, strokes, infections, traumatic brain injury, developmental abnormalities, autoimmune diseases, and genetic predispositions. Sometimes epilepsy is not easily diagnosed and treated due to the large diversity of symptoms. Undiagnosed and untreated seizures deteriorate over time, impair cognition, lead to injuries, and can sometimes result in death. This review gives details about epilepsy, its classification on the basis of ILAE, current therapeutics which are presently offered for the treatment of epilepsy. Despite of the fact that more than 30 different AED and antiseizure drugs are available, large number of epileptic patients fail to attain prolonged seizure independence. Poor onsite bioavailability of drugs due to Blood Brain Barrier poses a major challenge in drug delivery to brain. The present review covers the limitations with the state-of-the-art strategies for managing seizures and emphasizes the role of nanotechnology in overcoming these issues. Various nano-carriers like polymeric nanoparticles, dendrimers, lipidic nanoparticles such as solid lipid nanoparticles, nano-lipid carriers, have been explored for the delivery of anti-epileptic drugs to brain using oral and intranasal routes. Nano-carries protect the encapsulated drugs from degradation and provide a platform to deliver controlled release over prolonged periods, improved permeability and bioavailability at the site of action. The review also emphasises in details about the role of neuropeptides for the treatment of epilepsy.

show abstract

“…They are occasionally accompanied by loss of consciousness and control of bowel or bladder function. Approximately 80 % of global epilepsy cases are from low-and middle-income countries, where only about a quarter of patients obtain the necessary treatment due to financial limitations [2].…”

Section: Introductionmentioning

confidence: 99%

Exploring the Anticonvulsant Properties of a Celecoxib-Phospholipid Conjugate: Synthesis, Activation, and Evaluation of Cytotoxicity

Anjali,

Jawahar,

Praharsh Kumar

et al. 2024

Drug Res (Stuttg)

View full text Add to dashboard Cite

Background Epilepsy poses a significant global health challenge, particularly in regions with limited financial resources hindering access to treatment. Recent research highlights neuroinflammation, particularly involving cyclooxygenase-2 (COX-2) pathways, as a promising avenue for epilepsy management. Methods This study aimed to develop a Cyclooxygenase-2 inhibitor with potential anticonvulsant properties. A promising drug candidate was identified and chemically linked with phospholipids through docking analyses. The activation of this prodrug was assessed using phospholipase A2 (PLA2)-mediated hydrolysis studies. The conjugateʼs confirmation and cytotoxicity were evaluated using Fourier Transform Infrared Spectroscopy (FT-IR), Differential Scanning Calorimetry (DSC), and Sulphoramide B (SRB) assays. Results Docking studies revealed that the Celecoxib-Phospholipid conjugate exhibited a superior affinity for PLA2 compared to other drug-phospholipid conjugates. FT-IR spectroscopy confirmed the successful synthesis of the conjugate, while DSC analysis confirmed its purity and formation. PLA2-mediated hydrolysis experiments demonstrated selective activation of the prodrug depending on PLA2 concentration. SRB experiments indicated dose-dependent cytotoxic effects of Celecoxib, phospholipid non-toxicity, and efficient celecoxib-phospholipid conjugation. Conclusion This study successfully developed a Celecoxib-phospholipid conjugate with potential anticonvulsant properties. The prodrugʼs specific activation and cytotoxicity profile makes it a promising therapeutic candidate. Further investigation into underlying mechanisms and in vivo studies is necessary to assess its translational potential fully.

show abstract

Preparation, physicochemical and biopharmaceutical characterization of oxcarbazepine-loaded nanostructured lipid carriers as potential antiepileptic devices

Cited by 11 publications

References 40 publications

Biodegradable nanoparticles for the treatment of epilepsy: From current advances to future challenges

Biodegradable nanoparticles for the treatment of epilepsy: From current advances to future challenges

Nanotechnological advances in the treatment of epilepsy: a comprehensive review

Exploring the Anticonvulsant Properties of a Celecoxib-Phospholipid Conjugate: Synthesis, Activation, and Evaluation of Cytotoxicity

Contact Info

Product

Resources

About